Abbvie Inc.

Abbvie Deutschland Gmbh and Co Kg

Hervë Geneste

Karla Drescher

Berthold Behl

Michael Ochse

Jürgen Dinges

Clarissa Jakob

Loic Laplanche

The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof:  In formula I the variables Het, A, X, Y, Z, R1, R2, R3, R4, R5 and Q are as defined in the claims. The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A. Thus, the invention also relates to the use of the compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

Inhibitor compounds of phosphodiesterase type 10A

Growing community of inventors

Ludwigshafen, Germany

Hervë Geneste